Ankle-Arm Index as a Predictor of Cardiovascular Disease and Mortality in the Cardiovascular Health Study

Anne B. Newman, Lynn Shemanski, Teri A. Manolio, Mary Cushman, Maurice Mittelmark, Joseph F. Polak, Neil R. Powe, David Siscovick, for the Cardiovascular Health Study Collaborative Research Group

Abstract—Peripheral arterial disease (PAD) in the legs, measured noninvasively by the ankle-arm index (AAI) is associated with clinically manifest cardiovascular disease (CVD) and its risk factors. To determine risk of total mortality, coronary heart disease, or stroke mortality and incident versus recurrent CVD associated with a low AAI, we examined the relationship of the AAI to subsequent CVD events in 5888 older adults with and without CVD. The AAI was measured in 5888 participants ≥65 years old at the baseline examination of the Cardiovascular Health Study. All participants had a detailed assessment of prevalent CVD and were contacted every 6 months for total mortality and CVD events (including CVD mortality, fatal and nonfatal myocardial infarction, congestive heart failure, angina, stroke, and hospitalized PAD). The crude mortality rate at 6 years was highest (32.3%) in those participants with prevalent CVD and a low AAI (P<0.9), and it was lowest in those with neither of these findings (8.7%, P<0.01). Similar patterns emerged from analysis of recurrent CVD and incident CVD. The risk for incident congestive heart failure (relative risk [RR]=1.61) and for total mortality (RR=1.62) in those without CVD at baseline but with a low AAI remained significantly elevated after adjustment for cardiovascular risk factors. Hospitalized PAD events occurred months to years after the AAI was measured, with an adjusted RR of 5.55 (95% CI, 3.08 to 9.98) in those at risk for incident events. A statistically significant decline in survival was seen at each 0.1 decrement in the AAI. An AAI of <0.9 is an independent risk factor for incident CVD, recurrent CVD, and mortality in this group of older adults in the Cardiovascular Health Study. (Arterioscler Thromb Vasc Biol. 1999;19:538-545.)

Key Words: peripheral vascular diseases ■ ankle-arm index ■ ankle-brachial pressure index ■ cardiovascular diseases, epidemiology

Epidemiological studies have demonstrated that subclinical cardiovascular disease in one vascular bed is associated with the presence of clinical disease in another bed.1–5 as well as with subsequent cardiovascular and total mortality.6–12 Degrees of peripheral arterial disease (PAD) in the legs, as measured noninvasively, are common in older adults without overt signs and symptoms of PAD.5,13 Among the elderly, an index of subclinical atherosclerosis with the use of several noninvasive measures that include carotid stenosis and wall thickness by duplex scanning, ECG and echocardiographic abnormalities, a positive Rose questionnaire14 for angina, and an ankle-arm index (AAI) of <0.9 has been shown to be a strong predictor of total and cardiovascular morbidity and mortality in those without prior history of clinical cardiovascular disease at the baseline examination.15 PAD in the legs, as measured by progressive decrements in the AAI, was associated with a stepwise increase in cardiovascular risk factor levels as well as in the prevalence of myocardial infarction (MI), stroke, and congestive heart failure (CHF).5 Past prospective studies of the cardiovascular disease (CVD) risk associated with the presence of PAD have not distinguished between recurrent and incident CVD; thus, the increased risk of mortality may be partly because of the correlation of PAD with prevalent clinical CVD.

The goal of the present study was to evaluate the risk of cardiovascular morbidity and mortality associated with a marker of PAD, the presence of a low AAI (AAI <0.9). Follow-up data of 5888 older adults enrolled in the Cardiovascular Health Study (CHS) were examined for risk of subsequent cardiovascular events and mortality. We hypothesized that the presence of a low AAI in participants without clinical CVD would be associated with a degree of risk for cardiovascular events similar to that found in those with a low AAI and known clinical CVD.

Methods

The CHS is an ongoing observational study of 5888 adults ≥65 years old, including 2495 men and 3393 women. The initial cohort of CHS
participants was recruited from a defined sample of Medicare-
eligible persons between August 1989 and May 1990. Participants
were recruited from 4 US communities: Forsyth County, NC;
Sacramento County, Calif; Washington County, Md; and Pittsburgh,
Pa. Detailed descriptions of the CHS have been published.16-17 The
original sample of 5201 participants was primarily white: 148 (3%)
were black women and 96 (1.8%) were black men. A second cohort
of 687 black participants (431 women and 256 men) was enrolled
between June 1992 and June 1993, 3 years after the enrollment of
the original CHS cohort, to allow sample sizes sufficient for
subgroup analysis.
All of the CHS participants underwent a baseline medical history
and examination that included ECG, AAI, and pulmonary function
testing. During this examination, participants were classified in
accordance with the presence or absence of 6 preexisting CVDs: MI,
angina, CHF, stroke, transient ischemic attack (TIA), and intermit-
tent claudication. Participants with any of these 6 conditions were
classified as having prevalent CVD.
The methods of ascertainment of these conditions have been
described elsewhere.18-22 Briefly, baseline disease status was ascer-
tained from the medical history and confirmed by either the ECG,
appropriate prescription medication, hospital record review, or phy-
sician questionnaire. Participants with a history of coronary angio-
plasty, carotid endarterectomy, or bypass surgery were also consid-
ered to have prevalent CVD. Prevalent PAD was defined as a
positive Rose questionnaire14 for intermittent claudication or a
history of lower-extremity bypass surgery, angioplasty, or
amputation.
Descriptive variables from the baseline examination were chosen
for this analysis on the basis of associations with AAI as reported in
a prior cross-sectional analysis.3 These variables were age, sex, race,
cigarette use (current or past versus never), history of treated
hypertension or history of diabetes, systolic and diastolic blood
pressure (mm Hg), total cholesterol (mg/dL), HDL cholesterol
(mg/dL), triglycerides (mg/dL), fasting glucose (mg/dL), fasting
insulin (µU/mL), serum creatinine (mg/dL), and fibrinogen (mg/dL).
All blood was collected and analyzed at the time of baseline
examination according to laboratory methods previously reported.3
Major ECG abnormalities were determined by the CHS ECG
Reading Center according to a standard protocol and included
ventricular conduction defects, major Q or QS abnormalities, minor
Q or QS with ST-T–wave abnormalities, left ventricular hypertro-
phy, isolated major ST-T–wave changes, atrial fibrillation, or first-
degree atrioventricular block.
All participants underwent duplicate resting measurements of
the blood pressures used to create the AAI. The AAI is the ratio of
the ankle systolic blood pressure to the arm systolic blood pressure
and is >1.0 in normal adults.22 The AAI was measured by trained
technicians according to a standard protocol, previously described.3
Briefly, the participant was asked to lie flat on an examination table,
and after 5 minutes of rest, standard arm blood pressure cuffs
were applied to the right arm and to each ankle (with the lower end of
the bladder within 3 cm of the malleoli). After palpation of the brachial
and posterior tibial arteries, ultrasound gel was applied, and a
Doppler stethoscope (8 MHz, Huntleigh Technology, Inc) and a
standard mercury manometer were used to assess systolic blood
pressure in the right brachial artery and in each posterior tibial artery
in rapid succession. Measurements have been shown to be reliable
between observers, stable over time, and highly correlated between
left and right legs.11 We excluded 31 participants (0.5%) with AAI
≥ 1.5 in both legs at baseline because previous analyses5 indicated
that this is a falsely high level caused by noncompressible vessels in
the legs. One hundred and forty-three participants did not have
AAI data. Thus, 5714 participants of the total 5888 are included in
this analysis.
CHS methods for surveillance and ascertainment of CVD events
are described in detail in previous articles12,23 and are summarized as
follows. Participants were contacted by the CHS clinical centers
every 6 months in regard to subsequent hospitalizations and outpa-
tient visits for specific cardiovascular diagnoses including MI,
angina, CHF, stroke, TIA, and PAD. Total mortality included all
deaths and was documented by death certificates, inpatient records,
nursing home or hospice records, physician questionnaires, and
autopsy reports.
CVD mortality was defined to include death from CHD, MI, sudden
death, or stroke. Nonfatal events (whether a new or a repeat
event for a participant) were evaluated by review of all hospital
records (all ICD-9-CM codes), history and physical exams, discharge
summaries, and diagnostic and therapeutic procedures. Outpatient
records and physician questionnaires were evaluated for outpatient
MI, CHF, and stroke. Incident PAD events were defined by a review
of all inguinal hospitalizations or outpatient hospitalizations where
all records with an ICD-9 code of 440.2 or 443.9 or a mention of
peripheral vascular disease or claudication on the face sheet or in
the discharge summary were reviewed. A hospitalized PAD event
required the presence of ischemic leg pain and a consistent invasive
or noninvasive diagnostic test. Outpatient reports of PAD were
confirmed with the use of the AAI and thus were not independent of
the predictor variable. Therefore, only hospitalized PAD was used in
these analyses, because these diagnoses were made independently of
the CHS AAI measurement. Adjudication of each event was reached
by consensus.
For this analysis, the following categories of events were evalu-
tated: total mortality, CVD mortality (CHD and stroke), MI, angina,
CHF, stroke, and hospitalized PAD. Data through 6 years of
follow-up (mean, 5.1 years) for the original CHS cohort and 2 years
of follow-up for the black cohort (mean, 22 months) are reported
here.
Statistical Analysis
Participants were classified according to the presence or absence
of prevalent clinical CVD at baseline. Participants were also classified
as having a low AAI if the AAI was <0.9 in either leg. We chose
this cut point based on previous analyses in this population3 and in
other published articles.10-12 Associations of follow-up events with base-
line disease and of AAI groups were assessed by crude event rates,
Kaplan-Meier life tables, and Cox proportional hazards models with
an adjustment for age, gender, and other CVD risk factors. The
factors were those associated with a low AAI in previous cross-
sectional analyses3 and included race, past smoking, pack-years of
smoking, diabetes, total cholesterol, HDL cholesterol, triglyceride
level, fasting glucose, insulin, fibrinogen level, factor VII, and body
mass index. Cox proportional hazards models were used to assess
independent associations between an AAI <0.9 and various end
points. Cox models also were used to assess whether any interaction
between a low AAI and covariates was significant after all main
effects for the risk factors in the Cox models were included.
Associations were considered to be significant at P<0.01. All
analyses were performed with Statistical Analysis System
software.24
Results
At the baseline examination, 768 of 5714 participants
(13.4%) had an AAI of <0.9. This includes the added cohort
of 687 blacks whose baseline examination was 3 years after
the original cohort. Participants with a low AAI were older
and more likely to be male or black. In addition, those with
a low AAI were approximately twice as likely to have a history
of CVD at the baseline examination (46.7% versus 22%,
Table 1).
At 6 years of follow-up, crude and age- and
gender-adjusted event rates were calculated for total mortality as well
as for recurrent and incident CVD events. Rates were calcu-
lated separately for those with and without CVD at baseline.
The total mortality rate was highest in participants with
prevalent disease and a low AAI (32.3%) and lowest in those
with neither of these findings (8.7%, P<0.01, Table 2). Of
note, for those without prevalent CVD but with a low AAI,
the mortality rate was quite high (25.4%).
The 1446 participants with CVD at baseline were at a
higher risk for subsequent events than those without such
Within this higher-risk subgroup of CHS participants with CVD at baseline, the 3 factors of AAI, age, and male gender distinguished risk of total mortality, CVD mortality, total MI, CHF, and PAD. After adjustment for other CVD risk factors, risk ratios for total mortality, MI, and CHF were attenuated and CIs widened to include 1. The majority (74.7%) of the CHS cohort had no history of CVD at the baseline examination (Table 1). The relative risk (RR) and absolute risk for CVD events and mortality were significantly higher in those participants with a low AAI and no prevalent CVD for all events except stroke (Table 2). The RR of a low AAI for CVD mortality was higher than for total mortality (RR of 2.86 and 2.44, respectively, for CVD and total mortality), although CIs overlapped.

Compared with the use of history of CVD as a predictor of cardiovascular events, in those with no history of CVD the AAI is less sensitive but more specific. For total mortality, the sensitivity and specificity of an AAI <0.9 are 24% and 92%, respectively, compared with 44% sensitivity and 77% specificity for a history of CVD. A similar pattern is found when CVD mortality is used as the outcome event: a low AAI has 30% sensitivity and 91% specificity compared with 64% sensitivity and 77% specificity for history of CVD.

The rate of new clinical PAD events in the legs was significantly associated with the presence of a low AAI at the baseline examination in both groups (Table 2). Although the rate of PAD events was 6- to 11-fold higher in participants with low AAI, the absolute risk of the development of symptomatic PAD (11.7% in those with prevalent CVD versus 6.6% in those with no CVD) was less than or similar to that of other CVD events (including angina and stroke) and was much less than the risk for total mortality (32.3% of those with prevalent CVD, 25.4% for those without CVD).

To further evaluate the relationship of a low AAI to mortality, we focused on the 4268 participants with no CVD.

### Table 1. Characteristics of the CHS Cohort by AAI (n=5714)

<table>
<thead>
<tr>
<th>Characteristic</th>
<th>AAI&lt;0.9</th>
<th>AAI≥0.9</th>
</tr>
</thead>
<tbody>
<tr>
<td>(n=768)</td>
<td>(n=4946)</td>
<td></td>
</tr>
<tr>
<td>Age, y</td>
<td></td>
<td></td>
</tr>
<tr>
<td>65–69</td>
<td>141</td>
<td>1836</td>
</tr>
<tr>
<td>70–74</td>
<td>211</td>
<td>1608</td>
</tr>
<tr>
<td>75–79</td>
<td>200</td>
<td>956</td>
</tr>
<tr>
<td>80–84</td>
<td>141</td>
<td>407</td>
</tr>
<tr>
<td>85+</td>
<td>75</td>
<td>139</td>
</tr>
<tr>
<td>Gender</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Male</td>
<td>360</td>
<td>2072</td>
</tr>
<tr>
<td>Female</td>
<td>408</td>
<td>2874</td>
</tr>
<tr>
<td>Race</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Black</td>
<td>189</td>
<td>691</td>
</tr>
<tr>
<td>White</td>
<td>568</td>
<td>4223</td>
</tr>
<tr>
<td>Other</td>
<td>11</td>
<td>32</td>
</tr>
<tr>
<td>Prevalent CVD</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Yes</td>
<td>359</td>
<td>1087</td>
</tr>
<tr>
<td>No</td>
<td>409</td>
<td>3859</td>
</tr>
</tbody>
</table>

### Table 2. Cardiovascular Disease Morbidity and Mortality After 6 Years: The CHS

<table>
<thead>
<tr>
<th>Event</th>
<th>AAI&lt;0.9*</th>
<th>AAI≥0.9*</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>n (%)</td>
<td>n/1000 Person Years</td>
</tr>
<tr>
<td>Total mortality</td>
<td>116 (32.3)</td>
<td>78.4</td>
</tr>
<tr>
<td>CVD mortality</td>
<td>68 (18.9)</td>
<td>46.0</td>
</tr>
<tr>
<td>Total MI</td>
<td>62 (17.3)</td>
<td>45.7</td>
</tr>
<tr>
<td>Angina</td>
<td>28 (8.3)</td>
<td>49.9</td>
</tr>
<tr>
<td>CHF</td>
<td>63 (22.9)</td>
<td>56.7</td>
</tr>
<tr>
<td>Stroke</td>
<td>32 (11.3)</td>
<td>29.1</td>
</tr>
<tr>
<td>PAD</td>
<td>31 (11.7)</td>
<td>31.6</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Event</th>
<th>AAI&lt;0.9*</th>
<th>AAI≥0.9*</th>
<th>RR of Event Given Low AAI (95% CI)</th>
<th>RR of Event Given Low AAI (95% CI)</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Age-Gender Adjusted</td>
<td>Multivariate Adjustment</td>
<td>Age-Gender Adjusted</td>
<td>Multivariate Adjustment</td>
</tr>
<tr>
<td>Prevalent CVD at baseline</td>
<td></td>
<td></td>
<td>n / CI</td>
<td>n / CI</td>
</tr>
<tr>
<td>Total mortality</td>
<td>116 (32.3)</td>
<td>78.4</td>
<td>229 (21.1)</td>
<td>44.9</td>
</tr>
<tr>
<td>CVD mortality</td>
<td>68 (18.9)</td>
<td>46.0</td>
<td>104 (9.6)</td>
<td>20.4</td>
</tr>
<tr>
<td>Total MI</td>
<td>62 (17.3)</td>
<td>45.7</td>
<td>126 (11.6)</td>
<td>26.5</td>
</tr>
<tr>
<td>Angina</td>
<td>28 (8.3)</td>
<td>49.9</td>
<td>70 (17.7)</td>
<td>44.4</td>
</tr>
<tr>
<td>CHF</td>
<td>63 (22.9)</td>
<td>56.7</td>
<td>137 (15.0)</td>
<td>33.8</td>
</tr>
<tr>
<td>Stroke</td>
<td>32 (11.3)</td>
<td>29.1</td>
<td>78 (8.4)</td>
<td>18.6</td>
</tr>
<tr>
<td>PAD</td>
<td>31 (11.7)</td>
<td>31.6</td>
<td>24 (2.3)‡</td>
<td>5.0</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Event</th>
<th>AAI&lt;0.9*</th>
<th>AAI≥0.9*</th>
<th>RR of Event Given Low AAI (95% CI)</th>
<th>RR of Event Given Low AAI (95% CI)</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Age-Gender Adjusted</td>
<td>Multivariate Adjustment</td>
<td>Age-Gender Adjusted</td>
<td>Multivariate Adjustment</td>
</tr>
<tr>
<td>No prevalent CVD at baseline</td>
<td></td>
<td></td>
<td>n / CI</td>
<td>n / CI</td>
</tr>
<tr>
<td>Total mortality</td>
<td>104 (25.4)</td>
<td>59.3</td>
<td>337 (8.7)‡</td>
<td>17.4</td>
</tr>
<tr>
<td>CVD mortality</td>
<td>28 (6.9)</td>
<td>16.0</td>
<td>67 (1.7)‡</td>
<td>3.5</td>
</tr>
<tr>
<td>Total MI</td>
<td>33 (8.1)</td>
<td>20.0</td>
<td>169 (4.4)‡</td>
<td>9.0</td>
</tr>
<tr>
<td>Angina</td>
<td>51 (12.5)</td>
<td>31.8</td>
<td>353 (9.2)</td>
<td>19.3</td>
</tr>
<tr>
<td>CHF</td>
<td>57 (13.9)</td>
<td>34.9</td>
<td>212 (5.5)‡</td>
<td>11.3</td>
</tr>
<tr>
<td>Stroke</td>
<td>35 (8.6)</td>
<td>21.2</td>
<td>171 (4.4)</td>
<td>9.1</td>
</tr>
<tr>
<td>PAD</td>
<td>27 (6.6)</td>
<td>16.4</td>
<td>36 (0.9)‡</td>
<td>1.9</td>
</tr>
</tbody>
</table>

*For prevalent CVD at baseline, n=1446 (AAI<0.9, n=359; AAI≥0.9, n=1087); for no prevalent CVD at baseline, n=4268 (AAI<0.9, n=409; AAI≥0.9, n=3859).
P<0.01, continuity-adjusted χ² for difference between AAI<0.9 versus AAI≥0.9.

†P<0.01, Cox proportional hazards models.
at baseline and looked at the mortality rates by AAI in those with and without several important risk factors (Table 3). For each risk factor, the mortality rates were significantly higher in those with a low AAI than in those with a normal AAI. Whether the risk factor was present or absent, the RR of mortality was \(2\)-fold higher in those with a low AAI. For example, those with diabetes and a low AAI had a 31% mortality rate, whereas those with diabetes but a normal AAI had only a 12% mortality rate. Thus, within diabetics, the RR of mortality for those with a low AAI was only slightly higher than the RR of mortality in nondiabetics with a low AAI.

The proportion of blacks with a low AAI and no history of CVD was 16.5% (105 of 636) compared with 8.2% (298 of 3600) in the white participants. Although the majority of the black participants were from the new cohort, which was followed for only 2 years from the baseline examination, the presence of a low AAI was strongly related to subsequent mortality in those 636 black participants free of CVD at baseline (Table 3). Compared with white participants, the RR of mortality even with shorter follow-up time appears higher, although the CIs are wide. These stratified analyses gave similar results when CVD mortality and MI were evaluated.

Participants with an elevated serum cholesterol (>240 mg/dL) and a low AAI had a death rate similar to those with a cholesterol <240 and a low AAI (27.1% versus 24.7%). The relative risk of mortality in those with a low AAI was higher in the high-cholesterol subgroup (4.04 versus 2.03) and may be related to the lower mortality rate (7.1%) in those with a higher cholesterol but a normal AAI.

To further evaluate the independence of association between a low AAI and subsequent cardiovascular events in those without prevalent CVD, models were constructed that included the AAI and all variables associated univariately with a low AAI at baseline (Table 4). There were no significant interactions between a low AAI and covariates for any of the outcomes evaluated. For total mortality, the RR of a low AAI was attenuated somewhat at 1.62. Older age, male gender, higher serum creatinine, major ECG abnormality, and lower forced vital capacity were all associated with mortality independent of its association with a low AAI.
higher serum creatinine, major ECG abnormality, and lower forced vital capacity were also associated with incident CHF.

The risk for PAD remained quite high after adjustment, 5.55 (CI, 3.08 to 9.98), which suggested that the majority of those with an incident PAD event had a low AAI by screening for months to years before significant clinical manifestations. Current smoking and male gender were also strongly associated with incident PAD.

For all analyses, specification of the AAI as a continuous versus categorical variable in the model yielded consistent results.

In a previous study, we showed cross-sectionally that CVD and its risk factors were associated with a stepwise decrease in the AAI below 1.0. In the present study, we were able to evaluate the relationship of a decrease in AAI to total mortality in those with and without prevalent CVD at baseline (Figures 1 and 2). A striking increase in mortality was seen early in follow-up in the prevalent disease group at an AAI of <0.9. For participants with no prevalent disease at baseline, mortality rates were similar for those with an AAI of 0.8 to 0.9 after several years of follow-up. In addition, for those with no prevalent disease at baseline and a normal AAI, almost 80% of these older adults survived without cardiovascular morbidity (Figure 3). For each 0.1 decrement in the AAI below 1.0, event rates increased, which indicated a lack of a threshold for predicting mortality.

### Discussion

The majority of total and cardiovascular deaths in older adults occur in those with either clinical or subclinical CVD. Although easily documented by the presence of a low AAI, PAD is quite often asymptomatic in older adults. Even in participants without a history of CVD and without symptoms of claudication, ~10% of men and women >65 years old had an AAI <0.9. Thus, the AAI, as a marker of PAD, can provide important information about subclinical atherosclerosis.

Clearly, participants with a history of prevalent, clinically manifested CVD would be at highest risk for mortality and recurrent events. Even within this group, a low AAI was associated with increased age- and gender-adjusted risk of total and CVD mortality and remained independently associated with CVD mortality but not with total mortality or MI with multivariate adjustment. Regardless of clinical manifestation, participants with a reduction of the AAI of <0.9 are likely to have diffuse, advanced atherosclerosis. The magnitude of the risk related to a low AAI is similar to that found with the classification of participants with a more extensive battery of noninvasive tests, including echocardiography and carotid ultrasound. Cross-sectional analysis in the Atherosclerosis Risk in Communities Study (ARIC) cohort shows that the prevalence of an AAI <0.9 (low AAI) is uncommon in middle-aged and younger people. The associations with clinical and subclinical disease and the comparisons with angiography indicate that those with a low AAI have advanced significant atherosclerosis.

### Other covariates in model that were not independently associated with events were race, body mass index, diabetes, fasting insulin, glucose, fibrinogen, factor VII, cholesterol level, HDL, triglyceride level, history of cigarette use in the past, and pack-years of cigarette use.
The strong associations (2- to 3-fold hazard ratio) of a low AAI with total and CVD mortality, even in those without a history of CVD, confirm this. Thus, the AAI is not a useful screening test for early disease; rather, it is a very specific test for advanced disease. Its sensitivity and specificity for CVD mortality are 30% and 91%, respectively. This compares with a sensitivity and specificity of 43% and 70%, respectively, for left ventricular hypertrophy by echocardiogram as a predictor of CVD events.28 When calcium scores by electron-beam CT scan of the coronary arteries were reviewed to measure their ability to predict coronary events, a score threshold of 160 resulted in a sensitivity of 89% and specificity of 77%.29 In CHS, participants with a low AAI had a >2-fold risk of total and CVD mortality, even after the exclusion of those with clinical CVD. The risk was attenuated somewhat but still statistically significant with adjustment for traditional risk factors. A low AAI is not highly sensitive for outcomes, but its predictive value is roughly comparable to having a history of prior CVD.

It has been suggested that the AAI might be used to screen and target older adults for more aggressive risk factor intervention. Clearly, it cannot be considered in isolation because an AAI >0.9 does not rule out the presence of atherosclerosis. One potential role for the AAI is its use in the elimination of ≈10% of those >65 years old with no history of CVD from undergoing more expensive and sensitive test procedures. Alternatively, it may be useful to combine it with information from the ECG and electron-beam CT scan; the combination of information about several vascular beds may be the most sensitive and specific method to describe the anatomic extent of disease. The AAI is essentially a screening-level assessment for anatomic PAD in the legs, and when <0.9, it is quite sensitive and specific for obstruction compared with a full vascular laboratory evaluation.30 As a continuous variable, it must be remembered that AAI is a ratio of blood pressures and may also capture physiological information about systolic blood pressure and vascular stiffness. Nevertheless, when the AAI is used in older adults as a screening test with a cut point of 0.9, it also identifies a subgroup at higher risk for total and CVD mortality and is much less expensive and easier to interpret than methods that rely on vascular imaging, such as carotid duplex scanning.

The presence of a low AAI was associated with an increase in risk for all incident CVD morbidity and mortality except for stroke. In those at risk for incident CVD, the risk remained significantly elevated for total and CVD mortality, as well as CHF and PAD, but not for MI, angina, or stroke after multivariate adjustment. It may be that with longer follow-up, events would increase and CIs would narrow for other morbid events. It is also possible that the risk is highest in the short term and would attenuate with additional follow-up. These issues will be explored with further follow-up.

The association with CHF is interesting and may suggest that much of the CHF is related to atherosclerosis and perhaps myocardial ischemia. However, because the AAI is a ratio of systolic blood pressures, it may also be related to CHF as a measure of vascular stiffness. The diagnosis of CHF in the CHS cohort has been problematic in that it is often found in participants hospitalized for other reasons, such as chronic lung disease, pneumonia, arrhythmia, or postoperatively. Nevertheless, a preliminary report of CHF in this cohort shows that CHF is associated with myocardial ischemia, as well as left ventricular hypertrophy.31

The ability of a low AAI to predict hospitalization for symptomatic PAD is not surprising, because it is a screening test for atherosclerotic obstruction in the legs. Of note, the majority of these events occurred in those with a low AAI, yet some occurred in those with an AAI ≈0.9 at baseline. It is possible that obstruction developed over the years of follow-up or that occlusion occurred more suddenly. In addition, the cut point of 0.9 is arbitrary and will misclassify some participants with more mild atherosclerosis. Further analysis of the change over time and the types of procedures and symptoms in these individuals is ongoing. Caution must be used in the interpretation of these data, because only severe PAD identified by hospital records is included. Outpatient diagnoses of PAD in CHS included use of the AAI; thus, we could not make an unbiased assessment of its predictive value for outpatient events. Sensitivity and specificity of the AAI for PAD may be reduced if milder degrees of PAD had been included in the analyses.

The risk ratio for mortality in those with a low AAI was higher in blacks than whites, although the follow-up time was only ≈2 years for the majority of blacks in the CHS cohort. The black participants in CHS have been found to have more extensive clinical and subclinical atherosclerosis by multiple measures.32 The relative merits of different risk classification strategies in this group will require longer follow-up.

Previous studies have demonstrated the relationship between PAD by various measures and mortality in populations including subjects with hyperlipidemia or systolic hypertension.6–12 The RRs are similar in all of these studies. Previous studies, however, have not distinguished the risk of a low AAI for incident as opposed to recurrent CVD. Although the presence of a low AAI is strongly related to the presence of other clinical manifestations of CVD, a substantial proportion of older adults have no other clinical manifestations of CVD. The data demonstrate that the increased risk of CVD in those with low AAI is not solely related to the association of the AAI with clinically manifest CVD in these individuals. In addition, although a low AAI is associated with other cardiovascular risk factors,3 its association with CVD events is strong regardless of the presence or absence of these other risk factors.

Although symptoms of claudication do not occur until the AAI is ≈0.8,22 mortality risk appears to increase substantially...
at an AAI <0.9. The majority of the participants in this study had moderate reductions in the AAI (0.8 to 0.9) that would not be identified by medical history or other components of a routine physical examination, such as pulse palpation. Of note, those with an AAI ≥1.0 were at low risk of death or cardiovascular morbidity. Nevertheless, CVD cannot be excluded by the presence of a normal AAI. The AAI is reduced when there is obstruction to blood flow in the legs; thus, it is essentially a marker of fairly advanced atherosclerosis. As an initial screen, it is quite specific for subsequent CVD or mortality in older adults. Sensitivity may be improved by a combination of risk factors and measures of subclinical atherosclerosis.25 Follow-up of the CHS cohort for additional cardiovascular events will explore strategies that optimize the identification of older adults at high risk of CVD morbidity and mortality.

**Acknowledgments**

This study was supported by contracts N01-HL-85079, N01-HC-85080, N01-HC-85083, N01-HC-85084, N01-HC-85085, and N01-HC-85086 from the National Heart, Lung, and Blood Institute.

**Participating Institutions and Principal Staff**


Ankle-Arm Index as a Predictor of Cardiovascular Disease and Mortality in the Cardiovascular Health Study
Anne B. Newman, Lynn Shemanski, Teri A. Manolio, Mary Cushman, Maurice Mittelmark, Joseph F. Polak, Neil R. Powe and David Siscovick for the Cardiovascular Health Study Collaborative Research Group

Arterioscler Thromb Vasc Biol. 1999;19:538-545
doi: 10.1161/01.ATV.19.3.538

The online version of this article, along with updated information and services, is located on the World Wide Web at:
http://atvb.ahajournals.org/content/19/3/538

Permissions: Requests for permissions to reproduce figures, tables, or portions of articles originally published in Arteriosclerosis, Thrombosis, and Vascular Biology can be obtained via RightsLink, a service of the Copyright Clearance Center, not the Editorial Office. Once the online version of the published article for which permission is being requested is located, click Request Permissions in the middle column of the Web page under Services. Further information about this process is available in the Permissions and Rights Question and Answer document.

Reprints: Information about reprints can be found online at:
http://www.lww.com/reprints

Subscriptions: Information about subscribing to Arteriosclerosis, Thrombosis, and Vascular Biology is online at:
http://atvb.ahajournals.org/subscriptions/